TG Therapeutics Inc

+0.42 (+1.05%)

TG Therapeutics Initiates Rolling Submission Of Biologics License Application To U.S. FDA For Ublituximab In Combination With Umbralisib As A Treatment For Patients With Chronic Lymphocytic Leuk

Published: 12/01/2020 12:27 GMT
TG Therapeutics Inc (TGTX) - Tg Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination With Umbralisib As a Treatment for Patients With Chronic Lymphocytic Leukemia.
Tg Therapeutics Inc - Co Expects to Complete Bla Rolling Submission in First Half of 2021.